We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ono and Medarex Enter into Second Antibody Development Collaboration

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Ono Pharmaceutical Co., Ltd. and Medarex, Inc. have announced that they have entered into a collaborative agreement to research and develop a fully human anti-SDF-1 antibody for the potential treatment of multiple indications.

This is the second antibody development collaboration between Ono and Medarex. Anti-SDF-1 antibodies have been raised utilizing Medarex's UltiMAb Human Antibody Development System®.

Under this collaboration, Ono and Medarex expect to jointly work toward potential commercialization of a fully human antibody.

The two companies plan to share the costs and responsibilities of research and product development up to the completion of a Phase II clinical study.

Thereafter, each company will be fully responsible for any continued development and any commercialization in its exclusive territory; Medarex's exclusive territory is North America, and Ono's exclusive territory is all areas outside of North America.

"We are pleased to work with Ono as we continue to develop MDX-1106, our anti-PD1 antibody product candidate, and now for the development of a potential anti-SDF-1 antibody product candidate," said Dr. Donald L. Drakeman, President and CEO of Medarex.